Antibody-Drug Conjugates: Advancing from Magic Bullet to Biological Missile.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38306232.
- Also identified by DOI 10.1158/1078-0432.CCR-23-3414.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Precision drug development is focusing on targeting tumor cell surface proteins for therapeutic delivery, maximizing biomarker identified on-target damage to the tumor while minimizing toxicity. A recent article demonstrated high expression of B7-H4 antigen on resistant ovarian cancer cells and described preclinical activity of B7-H4-directed antibody-drug conjugate. See related article by Gitto et al., p. 1567.
Medical subject headings
- Immunoconjugates
- Ovarian Neoplasms